pmcid,first_author,title,year,type,sentence,question,answer,abstract_hash
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,"- BACKGROUND:: Approximately 7.3 million people with type 1 or type 2 diabetes (T1D/T2D) are treated with insulin, placing them at higher risk of severe hypoglycemia (SH).","How many people with type 1 or type 2 diabetes are treated with insulin, placing them at higher risk of severe hypoglycemia? (pmcid=10373001)","Approximately 7.3 million people with type 1 or type 2 diabetes (T1D/T2D) are treated with insulin, placing them at higher risk of severe hypoglycemia.",
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,"SH requires assistance of another individual and often necessitates the prompt administration of intravenous glucose, injectable glucagon, or both.",What are some of the treatment options for severe hypoglycemia that require assistance from another individual (pmcid=10373001)?,"The treatment options for severe hypoglycemia that require assistance from another individual include the prompt administration of intravenous glucose, injectable glucagon, or both.",
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,"Untreated, SH can progress to unconsciousness, seizures, coma, or death.",What are the potential consequences of untreated severe hypoglycemia? (pmcid=10373001),"Untreated severe hypoglycemia can progress to unconsciousness, seizures, coma, or death.",
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,"Before 2018, all glucagon rescue treatments required reconstitution.",What was required for all glucagon rescue treatments before 2018 (pmcid=10373001)?,Reconstitution,
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,The complexity of reconstitution is often a barrier to successful administration during a severe hypoglycemic event.,What is often a barrier to successful administration during a severe hypoglycemic event? (pmcid: 10373001),The complexity of reconstitution,
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,Studies suggest successful administration of glucagon emergency kits range from 6%-56% of the time.,What is the range of successful administration of glucagon emergency kits as suggested by studies? (pmcid: 10373001),The range of successful administration of glucagon emergency kits as suggested by studies is 6%-56% of the time.,
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,Second-generation glucagon treatments and glucagon analogs do not require reconstitution and have caregiver administration success rates ranging from 94%-100%.,What are the caregiver administration success rates for second-generation glucagon treatments and glucagon analogs? (pmcid=10373001),Caregiver administration success rates for second-generation glucagon treatments and glucagon analogs range from 94%-100%.,
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,Dasiglucagon is a glucagon analog administered via autoinjector or prefilled syringe and has been shown to result in rapid hypoglycemia recovery.,How is dasiglucagon administered and what has it been shown to result in (pmcid=10373001)?,Dasiglucagon is administered via autoinjector or prefilled syringe and has been shown to result in rapid hypoglycemia recovery.,
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,"Moreover, the autoinjector can be administered successfully 94% of the time by trained caregivers.",Was the autoinjector successfully administered by trained caregivers 94% of the time (pmcid=10373001)?,Yes,
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,Previous evaluation of costs in budget impact models (BIMs) demonstrated the potential for second-generation glucagon treatments to reduce the cost of SH events (SHEs).,How did previous evaluation of costs in budget impact models demonstrate the potential for second-generation glucagon treatments to reduce the cost of severe hypoglycemia events (SHEs) (pmcid=10373001)?,Previous evaluation of costs in budget impact models demonstrated that second-generation glucagon treatments have the potential to reduce the cost of severe hypoglycemia events (SHEs).,
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,The current model expands on those findings with a treatment pathway and accompanying assumptions reflecting important aspects of real-world SHE treatment.,What aspects of real-world SHE treatment are reflected in the treatment pathway and assumptions in the current model (pmcid=10373001)?,The treatment pathway and assumptions in the current model reflect important aspects of real-world severe hypoglycemia (SHE) treatment.,
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,"OBJECTIVE:: To evaluate the economic impact of dasiglucagon compared with available glucagon treatments for SHE management, considering direct cost of treatment and health care resource utilization.",What was the objective of the study conducted by Hinahara J regarding dasiglucagon compared with available glucagon treatments for SHE management (pmcid=10373001)?,"The objective of the study conducted by Hinahara J regarding dasiglucagon compared with available glucagon treatments for SHE management was to evaluate the economic impact, considering the direct cost of treatment and health care resource utilization.",
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,METHODS:: A 1-year BIM with a hypothetical US commercial health plan of 1 million lives was developed with a target population of individuals with diabetes at risk of SHE.,What type of model was developed in this study (pmcid=10373001)?,A budget impact model (BIM),
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,"The treatment pathway model included initial and secondary treatment attempts, treatment administration success and failure, plasma glucose (PG) recovery within 15 minutes, emergency medical services, emergency department (ED) visits, and hospitalizations.",What did the treatment pathway model for severe hypoglycemia include (pmcid=10373001)?,"The treatment pathway model for severe hypoglycemia included initial and secondary treatment attempts, treatment administration success and failure, plasma glucose (PG) recovery within 15 minutes, emergency medical services, emergency department (ED) visits, and hospitalizations.",
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,A 1-way sensitivity analysis was conducted to assess the sensitivity of the model to changes in parameter values.,Was a 1-way sensitivity analysis conducted in the study (pmcid=10373001)?,Yes.,
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,"RESULTS:: In a 1 million-covered lives population, it was estimated that 12,006 SHEs would occur annually.",How many severe hypoglycemic events were estimated to occur annually in a 1 million-covered lives population (pmcid=10373001)?,"12,006",
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,The higher rate of initial treatment success and PG recovery within 15 minutes associated with dasiglucagon treatment resulted in lower total health care costs.,What resulted in lower total health care costs associated with dasiglucagon treatment? (pmcid: 10373001),The higher rate of initial treatment success and PG recovery within 15 minutes associated with dasiglucagon treatment resulted in lower total health care costs.,
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,"Total SHE treatment costs with dasiglucagon were estimated at $13.4 million, compared with $16.7 million for injectable native glucagon, $20.7 million for nasal glucagon, $35.3 million for reconstituted glucagon, and $43.8 million for untreated individuals.",What were the total SHE treatment costs estimated with dasiglucagon compared to other treatments? (pmcid=10373001),"Total SHE treatment costs with dasiglucagon were estimated at $13.4 million, compared with $16.7 million for injectable native glucagon, $20.7 million for nasal glucagon, $35.3 million for reconstituted glucagon, and $43.8 million for untreated individuals.",
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,"Compared with untreated people, the number needed to treat (NNT) with dasiglucagon was 6 individuals to avoid 1 hospitalization.",How many individuals need to be treated with dasiglucagon to avoid 1 hospitalization? (pmcid=10373001),6 individuals,
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,NNT for this same comparison was 59 for injectable native glucagon and 27 for nasal glucagon.,What were the NNT values for injectable native glucagon and nasal glucagon in the comparison mentioned? (pmcid=10373001),"The NNT values for injectable native glucagon and nasal glucagon in the comparison mentioned were 59 and 27, respectively.",
10373001,Hinahara J,Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model,2022,bim,"CONCLUSIONS:: Treatment of SH with dasiglucagon decreased total direct medical costs by reducing health care resource utilization (emergency calls, emergency transports, ED visits, and hospitalizations) and accompanying costs associated with the treatment of SH.",How did treatment with dasiglucagon impact total direct medical costs in the treatment of severe hypoglycemia (pmcid=10373001)?,"Treatment of SH with dasiglucagon decreased total direct medical costs by reducing health care resource utilization (emergency calls, emergency transports, ED visits, and hospitalizations) and accompanying costs associated with the treatment of SH.",
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,- Background: Refractory angina (RA) is a chronic condition characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronary artery disease (CAD).,What is refractory angina characterized by? (pmcid=10982321),Refractory angina is characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronary artery disease (CAD).,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"Treatments for this condition have undergone major developments in recent decades; however, the treatment for RA remains a challenge for medicine.",What major developments have treatments for refractory angina undergone in recent decades? (pmcid=10982321),Treatments for refractory angina have undergone major developments in recent decades.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"In this sense, the Coronary Sinus Reducer System (CSRS) stands as the last line of therapy for ineligible patients for revascularization with reversible ischemia.",What does the Coronary Sinus Reducer System (CSRS) stand as for ineligible patients for revascularization with reversible ischemia? (pmcid=10982321),The Coronary Sinus Reducer System (CSRS) stands as the last line of therapy for ineligible patients for revascularization with reversible ischemia.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,The purpose of this report is to evaluate the potential burden on the National Health Service (NHS) and measure the health effects in terms of both quantity (life years) and quality-of-life aspects related to the reducer.,What is the purpose of the report (pmcid=10982321)?,The purpose of the report is to evaluate the potential burden on the National Health Service (NHS) and measure the health effects in terms of both quantity (life years) and quality-of-life aspects related to the reducer device.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,Methods: Two different economic evaluation models were developed as part of the analysis.,What type of economic evaluation models were developed as part of the analysis (pmcid=10982321)?,Two different economic evaluation models were developed as part of the analysis.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,The budget impact was developed to estimate the potential burden on the NHS from incremental uptake of the use of the reducer in the target population.,What was the purpose of developing the budget impact model in the study (pmcid=10982321)?,The purpose of developing the budget impact model in the study was to estimate the potential burden on the NHS from incremental uptake of the use of the reducer device in patients with refractory angina.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"The utility cost analysis compares and evaluates the quality of life and health resource use and costs between the two alternatives, based on the research of Gallone et al.",What research was the utility cost analysis based on (pmcid=10982321)?,The utility cost analysis was based on the research of Gallone et al.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,A deterministic and probabilistic sensitivity analysis was carried out to characterize the uncertainty around the parameters of the model.,Was a sensitivity analysis carried out to characterize the uncertainty around the parameters of the model (pmcid=10982321)?,Yes.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"Results: In the budget impact analysis (BIA), the reducer is shown to be more expensive in the first 2 years of the model, due to the gradual uptake in the market and the cost of the device.",What is shown to be more expensive in the first 2 years of the model in the budget impact analysis? (pmcid=10982321),The reducer device is shown to be more expensive in the first 2 years of the model in the budget impact analysis.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"Starting from the third year, assuming maintenance of effectiveness, there are savings in terms of resource absorption in direct healthcare costs arising from hospitalizations, emergency department accesses, coronarography, and visits avoided.",What type of costs are saved in terms of resource absorption in direct healthcare costs starting from the third year (pmcid=10982321)?,"Hospitalizations, emergency department accesses, coronarography, and visits",
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,"Conclusion: The BIA and cost-effectiveness model show that the reducer device, despite an increase in resources absorbed in the first years of implementation and use, has the potential to result in increased quality of life in patients with RA.",What do the budget impact model and cost-effectiveness model show about the reducer device in patients with refractory angina (pmcid=10982321)?,The budget impact model and cost-effectiveness model show that the reducer device has the potential to result in increased quality of life in patients with refractory angina.,
10982321,Fortunato A,A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina,2024,bim,These costs are largely offset in the short term by the improved clinical outcomes achievable leading to savings from the third year onward in the BIA and a dominance ratio in the cost–utility analysis.,What are the cost savings achieved in the budget impact model for the reducer device in patients with refractory angina (pmcid=10982321)?,"The cost savings achieved in the budget impact model for the reducer device in patients with refractory angina are largely offset in the short term by the improved clinical outcomes achievable, leading to savings from the third year onward.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,- Background: Recent developments improved outcomes in patients with autoimmune diseases.,What recent developments improved outcomes in patients with autoimmune diseases? (pmcid=10169960),Recent developments improved outcomes in patients with autoimmune diseases.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Biologics were approved as first-line treatment in selected naïve patients with plaque psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).",What were biologics approved as first-line treatment for in selected naïve patients? (pmcid=10169960),"Biologics were approved as first-line treatment for plaque psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA) in selected naïve patients.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Among them, secukinumab was most recently approved for treatment of active nr-axSpA in adults.",What was secukinumab most recently approved for the treatment of in adults (pmcid=10169960)?,Secukinumab was most recently approved for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adults.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"In this work, we assessed the budget impact of new secukinumab treatment options in the Italian market.",What did the work assess in the Italian market (pmcid=10169960)?,The work assessed the budget impact of new secukinumab treatment options in the Italian market.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,Methods: A cross-indication budget impact model was designed to estimate the effects of adding secukinumab in the Italian market from the National Health System perspective over a 3-year period.,What was the perspective of the budget impact model analysis (pmcid=10169960)?,The perspective of the budget impact model analysis in pmcid 10169960 was from the National Health System perspective.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"The model included all adults with PsO, PsA, AS and nr-axSpA, treated with biologics or biosimilars.",Who were included in the model for the budget impact analysis (pmcid=10169960)?,"All adults with Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis, treated with biologics or biosimilars.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"It compared costs between two scenarios, secukinumab availability or absence, for the four diseases combined and taken individually.",What costs were compared in the study for the four diseases combined and taken individually (pmcid=10169960)?,"The study compared costs between two scenarios, secukinumab availability or absence, for the four diseases combined and taken individually.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,A sensitivity analyses was conducted.,Was a sensitivity analysis conducted (pmcid=10169960)?,Yes.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Results: There were 68,121 adult patients treated with biologics in 2021 and 68,341 in 2023.",How many adult patients were treated with biologics in 2021 and 2023? (pmcid=10169960),"68,121 adult patients were treated with biologics in 2021 and 68,341 in 2023.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,The budget impact analysis (BIA) on all indications showed a cost reduction of €33.7 million (− 1.5%) over 3 years with the introduction of secukinumab.,What cost reduction was observed over 3 years with the introduction of secukinumab in the budget impact analysis (pmcid=10169960)?,€33.7 million,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"PsA patients had the highest saving (− €34.9 million), followed by PsO patients (− €7.8 million).",How much savings did PsA patients have in the study conducted by Cortesi PA? (pmcid=10169960),PsA patients had a savings of €34.9 million in the study conducted by Cortesi PA.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,Cost saving in PsO patients was balanced by increased budget reported in AS patients (+ €8.0 million).,How was the budget impact of Secukinumab in Italy distributed among Psoriasis and Ankylosing Spondylitis patients (pmcid=10169960)?,"The budget impact of Secukinumab in Italy was distributed as cost saving in Psoriasis patients and an increased budget in Ankylosing Spondylitis patients. Specifically, there was a cost saving of €8.0 million in Psoriasis patients, while there was an increased budget of €8.0 million in Ankylosing Spondylitis patients.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"In nr-axSpA patients, secukinumab reported no significant budget increase (+ 1.0%).",What was the budget increase reported for secukinumab in nr-axSpA patients (pmcid=10169960)?,"In nr-axSpA patients, secukinumab reported no significant budget increase (+ 1.0%).",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Conclusion: This BIA accounted for the new indication of secukinumab in nr-axSpA patients, reporting no significant changes in the required budget and adding an effective treatment option.",What indication of secukinumab was accounted for in the budget impact model (pmcid=10169960)?,The budget impact model accounted for the new indication of secukinumab in non-radiographic axial spondyloarthritis (nr-axSpA) patients.,
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,"Considering all indications, secukinumab is a sustainable treatment option.",Is secukinumab considered a sustainable treatment option for all indications (pmcid=10169960)?,"Yes, considering all indications, secukinumab is considered a sustainable treatment option according to the information provided in the context.",
10169960,Cortesi PA,"A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy",2023,bim,Supplementary Information: The online version contains supplementary material available at 10.1007/s41669-023-00404-3.,What supplementary material is available in the online version of the article (pmcid=10169960)?,"The supplementary material available in the online version of the article with pmcid 10169960 includes additional information related to the budget impact model of Secukinumab for the treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis in Italy.",
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,"- BACKGROUND:: In 2017, the FDA approved the adjuvanted recombinant zoster vaccine (RZV) for the prevention of herpes zoster (HZ) in immunocompetent adults aged 50 years and older.",What vaccine was approved by the FDA in 2017 for the prevention of herpes zoster in immunocompetent adults aged 50 years and older? (pmcid=10391059),The adjuvanted recombinant zoster vaccine (RZV) was approved by the FDA in 2017 for the prevention of herpes zoster in immunocompetent adults aged 50 years and older.,
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,RZV joined zoster vaccine live (ZVL) as U.S.-marketed vaccines against HZ.,What vaccines are being compared in the study (pmcid=10391059)?,Recombinant zoster vaccine (RZV) and zoster vaccine live (ZVL),
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,The Advisory Committee on Immunization Practices preferentially recommended use of RZV over ZVL.,What did the Advisory Committee on Immunization Practices preferentially recommend the use of? (pmcid=10391059),RZV,
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,"In order to inform population-based decision makers (PBDMs) about the incremental clinical and economic impact of RZV adoption, budget impact (BI) models may be used.",What may be used to inform population-based decision makers about the incremental clinical and economic impact of RZV adoption (pmcid=10391059)?,Budget impact (BI) models may be used.,
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,"Populating such models with national data can inform PBDMs about the incremental value of RZV adoption nationally; however, heterogeneity across health plans requires the inclusion of plan-specific data to ensure the relevance of modeling outcomes for plan-specific decision makers.",What can inform PBDMs about the incremental value of RZV adoption nationally (pmcid=10391059)?,Populating such models with national data can inform PBDMs about the incremental value of RZV adoption nationally.,
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,"OBJECTIVE:: To investigate the clinical and economic outcomes associated with the adoption of RZV in nationally representative populations with commercial and Medicare coverage and to demonstrate the effect of the heterogeneity of health plans using real-world data from a large, integrated delivery network (IDN).",What was the objective of the study (pmcid=10391059)?,"The objective of the study was to investigate the clinical and economic outcomes associated with the adoption of recombinant zoster vaccination (RZV) in nationally representative populations with commercial and Medicare coverage, and to demonstrate the effect of the heterogeneity of health plans using real-world data from a large, integrated delivery network (IDN).",
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,METHODS:: We used a publicly available BI model.,What type of budget impact model was used in the study (pmcid=10391059)?,The study used a publicly available budget impact model.,
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,"The model accounts for national and IDN-collected population characteristics (size, age distribution) and epidemiological data (incidence of HZ and complications, HZ recurrence rate), vaccine characteristics from randomized controlled trials and observational studies (efficacy, waning, second dose compliance for RZV, adverse event rate), national costs (vaccine, direct medical for HZ, complications, and vaccine adverse events), and current and anticipated vaccine coverage.","What data does the model account for in terms of population characteristics, epidemiological data, vaccine characteristics, national costs, and vaccine coverage? (pmcid=10391059)","The model accounts for national and IDN-collected population characteristics (size, age distribution), epidemiological data (incidence of HZ and complications, HZ recurrence rate), vaccine characteristics from randomized controlled trials and observational studies (efficacy, waning, second dose compliance for RZV, adverse event rate), national costs (vaccine, direct medical for HZ, complications, and vaccine adverse events), and current and anticipated vaccine coverage.",
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,"We assessed incremental clinical (HZ cases and complications) and economic (per-member-per-month [PMPM] costs) impact at 5-year to 15-year time horizons, comparing scenarios where RZV is solely implemented with one where only ZVL is utilized.",What scenarios were compared in terms of incremental clinical and economic impact in the study (pmcid=10391059)?,The study compared scenarios where only the recombinant zoster vaccine (RZV) is implemented with scenarios where only the zoster vaccine live (ZVL) is utilized in terms of incremental clinical and economic impact.,
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,"RESULTS:: Following the adoption of RZV, the incremental HZ cases avoided over 5 and 15 years were estimated to be 1,800 and 15,000 for a commercial plan, 3,800 and 21,000 for a Medicare plan, and 8,600 and 71,000 for a specific IDN.",How many incremental herpes zoster cases were estimated to be avoided over 5 and 15 years for a specific IDN? (pmcid=10391059),"8,600 and 71,000",
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,"The incremental PMPM budget impact over the same time horizons was estimated to be $0.42 and $0.31, respectively, for a commercial plan, $0.35 and $0.10 for a Medicare plan, and $0.39 and $0.25 for a specific IDN.",What was the incremental PMPM budget impact estimated to be for a commercial plan over the same time horizons (pmcid=10391059)?,The incremental PMPM budget impact for a commercial plan was estimated to be $0.42 and $0.31 over the same time horizons.,
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,"The differences in results across plans resulted from the population age distribution, the vaccine copay (applied in the Medicare scenario only), the vaccine coverage in the plan, and other plan-specific factors affecting disease epidemiology and costs per case of HZ.",What factors influenced the differences in results across plans in the study (pmcid=10391059)?,"The factors that influenced the differences in results across plans in the study were the population age distribution, the vaccine copay (applied in the Medicare scenario only), the vaccine coverage in the plan, and other plan-specific factors affecting disease epidemiology and costs per case of HZ.",
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,"CONCLUSIONS:: Model projections indicated that RZV adoption avoided HZ cases and related complications, with the PMPM budget impact dependent on plan-specific factors.",What did the model projections indicate about RZV adoption and its impact on HZ cases and related complications (pmcid=10391059)?,The model projections indicated that RZV adoption avoided HZ cases and related complications.,
10391059,Patterson BJ,Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model,2020,bim,"As health gains increased over time, the incremental costs incurred were found to decrease as the shorter-term costs of adopting the new vaccine were increasingly offset by the longer-term benefits of vaccination.",What were the incremental costs incurred found to decrease over time as health gains increased (pmcid=10391059)?,The incremental costs incurred were found to decrease over time as health gains increased.,
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,- Aims:: The budgetary consequences of increasing dronedarone utilization for treatment of atrial fibrillation were evaluated from a US payer perspective.,What were the budgetary consequences evaluated in the study (pmcid=10402749)?,The budgetary consequences evaluated in the study were the increasing utilization of dronedarone for the treatment of atrial fibrillation from a US payer perspective.,
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,"Materials & methods:: A budget impact model over a 5-year time horizon was developed, including drug-related costs and risks for long-term clinical outcomes (LTCOs).",What time horizon was considered in the budget impact model developed for dronedarone compared with other rhythm control strategies (pmcid=10402749)?,The budget impact model considered a 5-year time horizon.,
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,"Treatments included antiarrhythmic drugs (AADs; dronedarone, amiodarone, sotalol, propafenone, dofetilide, flecainide), rate control medications, and ablation.",What treatments were included in the study (pmcid=10402749)?,"The treatments included in the study were antiarrhythmic drugs (AADs) such as dronedarone, amiodarone, sotalol, propafenone, dofetilide, and flecainide, as well as rate control medications and ablation.",
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,Direct comparisons and temporal and non-temporal combination scenarios investigating treatment order were analyzed as costs per patient per month (PPPM).,What was analyzed as costs per patient per month in the study (pmcid=10402749)?,Direct comparisons and temporal and non-temporal combination scenarios were analyzed as costs per patient per month (PPPM) in the study.,
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,"Results:: By projected year 5, costs PPPM for dronedarone versus other AADs decreased by $37.69 due to fewer LTCOs, treatment with dronedarone versus ablation or rate control medications + ablation resulted in cost savings ($359.94 and $370.54, respectively), and AADs placed before ablation decreased PPPM costs by $242 compared with ablation before AADs.",What were the projected cost savings for treatment with dronedarone versus ablation or rate control medications + ablation by year 5 (pmcid=10402749)?,"By year 5, the projected cost savings for treatment with dronedarone versus ablation or rate control medications + ablation were $359.94 and $370.54, respectively.",
10402749,Ken-Opurum J,A value-based budget impact model for dronedarone compared with other rhythm control strategies,2023,bim,Conclusion:: Increased dronedarone utilization demonstrated incremental cost reductions over time.,Did increased dronedarone utilization result in incremental cost reductions over time (pmcid=10402749)?,"Yes, increased dronedarone utilization resulted in incremental cost reductions over time according to the study with pmcid=10402749.",
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,"- Purpose: To estimate the budget impact of selinexor, bortezomib, and dexamethasone (XVd) in patients with previously treated multiple myeloma (MM) from the perspective of a private third-party payer and Medicare in the US.",What is the purpose of the study (pmcid=8203300)?,"The purpose of the study is to estimate the budget impact of selinexor, bortezomib, and dexamethasone (XVd) in patients with previously treated multiple myeloma (MM) from the perspective of a private third-party payer and Medicare in the US.",
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,"Methods: The introduction of XVd as an option for patients with previously treated MM compared to no introduction of XVd was considered from a private third-party US payer (with 1,000,000 members) and a Medicare perspective in one-year increments for 3 years.",What perspectives were considered in the budget impact model for the introduction of XVd for previously treated MM patients (pmcid=8203300)?,"The perspectives considered in the budget impact model for the introduction of XVd for previously treated MM patients were a private third-party US payer (with 1,000,000 members) and a Medicare perspective.",
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,"Total annual treatment costs were calculated as the sum of drug costs, costs of treating serious treatment emergent adverse events (grade ≥3), ongoing best supportive care costs, and mortality costs.",What costs were included in the calculation of total annual treatment costs (pmcid=8203300)?,"The costs included in the calculation of total annual treatment costs were drug costs, costs of treating serious treatment emergent adverse events (grade ≥3), ongoing best supportive care costs, and mortality costs.",
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,"Results: The absolute budget impact (Millions, USD) of including XVd from a private third-party payer plan perspective was $0.06, $0.07, $0.08 and $0.22 for years 1, 2, 3, and overall, respectively.","What was the absolute budget impact of including XVd from a private third-party payer plan perspective for years 1, 2, 3, and overall? (pmcid=8203300)","The absolute budget impact of including XVd from a private third-party payer plan perspective was $0.06 for year 1, $0.07 for year 2, $0.08 for year 3, and $0.22 overall.",
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,"The relative budget impact of including XVd was 0.33%, 0.40%, 0.43%, and 0.38% for years 1, 2, 3, and overall, respectively.","What was the relative budget impact of including XVd for years 1, 2, 3, and overall (pmcid=8203300)?","The relative budget impact of including XVd was 0.33% for year 1, 0.40% for year 2, 0.43% for year 3, and 0.38% overall.",
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,"This translated to a per member per month (PMPM) budget impact of $0.005, $0.006, $0.007, and $0.006 (USD), for years 1, 2, 3, and overall, respectively.","What was the per member per month (PMPM) budget impact for Selinexor, Bortezomib, and Dexamethasone in the study (pmcid=8203300)?","The per member per month (PMPM) budget impact for Selinexor, Bortezomib, and Dexamethasone in the study was $0.005, $0.006, $0.007, and $0.006 (USD) for years 1, 2, 3, and overall, respectively.",
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,"From a Medicare perspective, the absolute budget impact (Millions, USD) of including XVd was $29.68, $36.62, $39.42 and $105.72 for years 1, 2, 3, and overall, respectively.",What was the absolute budget impact of including XVd from a Medicare perspective (pmcid=8203300)?,"The absolute budget impact of including XVd from a Medicare perspective was $29.68 million for year 1, $36.62 million for year 2, $39.42 million for year 3, and $105.72 million overall.",
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,"The relative budget impact of including XVd was 0.33%, 0.40%, 0.43%, and 0.38% percent for years 1, 2, 3, and overall, respectively.","What was the relative budget impact of including XVd for years 1, 2, 3, and overall (pmcid=8203300)?","The relative budget impact of including XVd was 0.33% for year 1, 0.40% for year 2, 0.43% for year 3, and 0.38% overall.",
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,"This translated to a PMPM budget impact of $0.041, $0.051, $0.054, and $0.049 (USD), for years 1, 2, 3, and overall, respectively.","What was the PMPM budget impact for years 1, 2, 3, and overall for the treatment of previously treated multiple myeloma (pmcid=8203300)?","The PMPM budget impact for years 1, 2, 3, and overall for the treatment of previously treated multiple myeloma was $0.041, $0.051, $0.054, and $0.049 (USD), respectively.",
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,Sensitivity analyses showed general consistency with the base-case findings.,Did the sensitivity analyses show general consistency with the base-case findings (pmcid=8203300)?,"Yes, the sensitivity analyses showed general consistency with the base-case findings in the study on the US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma (pmcid=8203300).",
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,Conclusion: Understanding the potential budget impact of new therapies in MM is vital for payers to manage spending and assess treatment value.,What is vital for payers to manage spending and assess treatment value in multiple myeloma (pmcid=8203300)?,Understanding the potential budget impact of new therapies in multiple myeloma is vital for payers to manage spending and assess treatment value.,
8203300,Dolph M,"US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma",2021,bim,The introduction of XVd presents a manageable budget impact for a third-party US payer and Medicare.,What is the budget impact of the introduction of XVd for a third-party US payer and Medicare (pmcid=8203300)?,The budget impact of the introduction of XVd for a third-party US payer and Medicare is manageable.,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"- Background and Objective: In Germany, influenza vaccination is mainly advised for persons aged 60 years and over and individuals with health risks.",What age group is influenza vaccination mainly advised for in Germany (pmcid=10570167)?,"In Germany, influenza vaccination is mainly advised for persons aged 60 years and over.",
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"Since 2021, an inactivated, quadrivalent high-dose influenza vaccine (IIV4-HD) has been recommended for persons aged 60 years and over.",What vaccine has been recommended for persons aged 60 years and over since 2021 (pmcid=10570167)?,"An inactivated, quadrivalent high-dose influenza vaccine (IIV4-HD)",
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,The aim of this study was to calculate the impact of vaccinating the German population aged 60 years and over with IIV4-HD compared to standard-dose influenza vaccines (IIV4-SD) with regard to health outcomes and costs.,What was the aim of this study (pmcid=10570167)?,The aim of the study with pmcid=10570167 was to calculate the impact of vaccinating the German population aged 60 years and over with a Quadrivalent High-Dose Inactivated Influenza Vaccine (IIV4-HD) compared to standard-dose influenza vaccines (IIV4-SD) with regard to health outcomes and costs.,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Methods: An age-stratified deterministic compartment model was built to simulate the course of influenza infection for the German population in the season 2019/20.,What season was simulated in the age-stratified deterministic compartment model for the German population? (pmcid=10570167),The season simulated in the age-stratified deterministic compartment model for the German population was the season 2019/20.,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Probabilities for health outcomes and cost data were searched from the literature and were used to compare the influenza-related health and economic effects for different scenarios.,What were the probabilities for health outcomes and cost data used for in the study (pmcid=10570167)?,The probabilities for health outcomes and cost data were used to compare the influenza-related health and economic effects for different scenarios in the study with pmcid=10570167.,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Perspectives were those of the statutory health insurance and the society.,What were the perspectives considered in the study (pmcid=10570167)?,The perspectives considered in the study were those of the statutory health insurance and the society.,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Deterministic sensitivity analyses were conducted.,Were deterministic sensitivity analyses conducted in the study? (pmcid=10570167),"Yes, deterministic sensitivity analyses were conducted in the study.",
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"Results: From the statutory health insurance perspective, vaccinating the German population aged 60 years and over with IIV4-HD would have prevented 277,026 infections (− 1.1%) with an increase of overall direct costs of €224 million (+ 40.1%) compared with IIV4-SD.","How many infections would have been prevented by vaccinating the German population aged 60 years and over with IIV4-HD compared to IIV4-SD, from the statutory health insurance perspective? (pmcid=10570167)","277,026 infections",
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,"A separate analysis showed that increased vaccination of 75% (World Health Organization recommendation for older age groups) in persons aged 60 years and over using IIV4-SD only would prevent 1,289,648 infections (− 5.1%) and would save costs from a statutory health insurance perspective of €103 million (− 13.2%) compared with IIV4-HD at actual vaccination rates.",How many infections would be prevented by increased vaccination of 75% in persons aged 60 years and over using IIV4-SD only? (pmcid=10570167),"1,289,648 infections",
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Conclusions: The modeling approach offers important insights into the epidemiological and budgetary impact of different vaccination scenarios.,What insights does the modeling approach offer into the epidemiological and budgetary impact of different vaccination scenarios? (pmcid=10570167),The modeling approach offers important insights into the epidemiological and budgetary impact of different vaccination scenarios.,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Achieving a higher vaccination coverage with IIV4-SD in persons aged 60 years and over would result in lower costs and fewer influenza infections compared with the scenario with IIV4-HD and actual vaccination rates.,What would be the result of achieving a higher vaccination coverage with IIV4-SD in persons aged 60 years and over compared to the scenario with IIV4-HD and actual vaccination rates (pmcid=10570167)?,Lower costs and fewer influenza infections,
10570167,Pahmeier K,Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model,2023,bim,Supplementary Information: The online version contains supplementary material available at 10.1007/s40273-023-01299-y.,What supplementary material is available in the online version of the article (pmcid=10570167)?,"The supplementary material available in the online version of the article with pmcid=10570167 includes additional information related to the study, such as data, tables, figures, or additional analysis.",
8382623,Altaf N,A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective,2021,bim,"- Purpose: Improvement in long-term outcomes through innovative, cost-effective medical technologies is a focus for endovascular procedures aimed at treating symptomatic lower-limb peripheral arterial disease (PAD).",What is the focus of endovascular procedures aimed at treating symptomatic lower-limb peripheral arterial disease (PAD) according to the abstract sentence provided? (pmcid=8382623),"The focus of endovascular procedures aimed at treating symptomatic lower-limb peripheral arterial disease (PAD) is on improvement in long-term outcomes through innovative, cost-effective medical technologies.",
8382623,Altaf N,A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective,2021,bim,The advent of drug-eluting stents (DES) has improved symptomatic PAD treatment via a reduction in high rates of target lesion revascularisation (TLR).,How has the advent of drug-eluting stents improved treatment for symptomatic PAD patients? (pmcid=8382623),The advent of drug-eluting stents has improved treatment for symptomatic PAD patients by reducing high rates of target lesion revascularisation (TLR).,
8382623,Altaf N,A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective,2021,bim,"The present study aimed to compare the 5-year financial impact of treatment with Eluvia, a new paclitaxel-eluting stent, versus treatment with Zilver PTX, a drug-coated stent, among patients in Australia by developing a budget impact model (BIM).",What was the aim of the present study (pmcid=8382623)?,"The aim of the present study was to compare the 5-year financial impact of treatment with Eluvia, a new paclitaxel-eluting stent, versus treatment with Zilver PTX, a drug-coated stent, among patients in Australia by developing a budget impact model (BIM).",
8382623,Altaf N,A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective,2021,bim,"Methods: A BIM was developed from an Australian public hospital payer perspective using Australian national cost weights (AUD), published literature, and public hospital audit data.",What perspective was used in developing the Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease in Australia? (pmcid=8382623),The Budget Impact Model was developed from an Australian public hospital payer perspective.,
8382623,Altaf N,A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective,2021,bim,"Clinical outcomes, including clinically driven TLRs (CD-TLRs), adverse events, and length of stay, were based on the 2-year results of the IMPERIAL trial, which compared Eluvia DES to Zilver PTX.",What trial results were used to inform the clinical outcomes in the budget impact model (pmcid=8382623)?,The 2-year results of the IMPERIAL trial were used to inform the clinical outcomes in the budget impact model.,
8382623,Altaf N,A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective,2021,bim,"Results: Assuming EVP eligibility rate of 80% and DES uses rate ranging from 10 to 28% (superficial femoral artery lesions only), the 5-year model forecasted a treatment population between 14,428 and 40,399 patients.",What did the 5-year model forecast in terms of treatment population for patients with symptomatic lower-limb peripheral arterial disease using drug-eluting stents (pmcid=8382623)?,"The 5-year model forecasted a treatment population between 14,428 and 40,399 patients for patients with symptomatic lower-limb peripheral arterial disease using drug-eluting stents.",
8382623,Altaf N,A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective,2021,bim,"The model estimated 1499–4198 fewer CD-TLRs and 16,515–46,243 fewer hospital days with Eluvia DES use.",How many fewer hospital days were estimated with Eluvia DES use in patients with symptomatic lower-limb peripheral arterial disease (pmcid=8382623)?,"16,515–46,243 fewer hospital days were estimated with Eluvia DES use in patients with symptomatic lower-limb peripheral arterial disease.",
8382623,Altaf N,A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective,2021,bim,This translated to 5-year potential savings of $4.3–$12.1 million to the Australian public hospital payer attributable to reduced CD-TLRs for Eluvia DES and $33.1–$92.6 million to Australian public hospitals owing to reduced adverse events and hospital bed days.,What were the potential savings to the Australian public hospital payer attributable to reduced CD-TLRs for Eluvia DES and reduced adverse events and hospital bed days (pmcid: 8382623)?,The potential savings to the Australian public hospital payer were $4.3–$12.1 million attributable to reduced CD-TLRs for Eluvia DES and $33.1–$92.6 million owing to reduced adverse events and hospital bed days.,
8382623,Altaf N,A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective,2021,bim,Conclusion: Eluvia DES use as treatment for symptomatic lower-limb PAD could lead to potential savings for the Australian public healthcare system based on improved patient outcomes.,What potential savings could the use of Eluvia DES lead to for the Australian public healthcare system (pmcid=8382623)?,The use of Eluvia DES could lead to potential savings for the Australian public healthcare system based on improved patient outcomes.,
8382623,Altaf N,A Budget Impact Model for the use of Drug-Eluting Stents in Patients with Symptomatic Lower-Limb Peripheral Arterial Disease: An Australian Perspective,2021,bim,Supplementary Information: The online version contains supplementary material available at 10.1007/s00270-021-02848-8.,What supplementary material is available in the online version of the article (pmcid=8382623)?,The supplementary material available in the online version of the article with pmcid=8382623 includes additional information related to the budget impact model for the use of drug-eluting stents in patients with symptomatic lower-limb peripheral arterial disease from an Australian perspective.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"- Background: In South Africa, diabetes prevalence is expected to reach 5.4 million by 2030.",What is the expected diabetes prevalence in South Africa by 2030 (pmcid=10442735)?,The expected diabetes prevalence in South Africa by 2030 is 5.4 million.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"In South Africa, diabetes-related complications severely impact not only patient health and quality of life but also the economy.",How do diabetes-related complications impact both patient health and the economy in South Africa (pmcid=10442735)?,"Diabetes-related complications in South Africa severely impact both patient health and quality of life, as well as the economy.",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,Objective: The Diabetes Nurse Educator (DNE) study assessed the benefit of adding the MyDiaCare program to standard of care for managing patients with type 1 and type 2 diabetes in South Africa.,What benefit did the Diabetes Nurse Educator (DNE) study assess by adding the MyDiaCare program to standard of care for managing patients with type 1 and type 2 diabetes in South Africa (pmcid: 10442735)?,The Diabetes Nurse Educator (DNE) study assessed the benefit of adding the MyDiaCare program to standard of care for managing patients with type 1 and type 2 diabetes in South Africa.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,An economic study was also performed to estimate the budget impact of adding MyDiaCare to standard of care for patients with type 2 diabetes older than 19 years treated in the South African private health care sector.,What was the purpose of the economic study conducted in the South African private health care sector (pmcid=10442735)?,The purpose of the economic study conducted in the South African private health care sector was to estimate the budget impact of adding MyDiaCare to the standard of care for patients with type 2 diabetes older than 19 years.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Methods: The real-world DNE study was designed as an observational, retrospective, multicenter, single-group study.",What type of study design was used in the real-world DNE study (pmcid=10442735)?,"The real-world DNE study used an observational, retrospective, multicenter, single-group study design.",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,Eligible patients were older than 18 years and had at least 6 months of participation in the MyDiaCare program.,How long did eligible patients have to participate in the MyDiaCare program? (pmcid=10442735),Eligible patients had to have at least 6 months of participation in the MyDiaCare program.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,The MyDiaCare program combines a patient mobile app and a health care professional platform with face-to-face visits with a DNE.,What does the MyDiaCare program combine according to the abstract sentence? (pmcid=10442735),The MyDiaCare program combines a patient mobile app and a health care professional platform with face-to-face visits with a Diabetes Nurse Educator (DNE).,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"The benefit of MyDiaCare was assessed by the changes in glycated hemoglobin (HbA1c) levels, the proportion of patients achieving clinical and biological targets, adherence to care plans, and satisfaction after 6 months of participating in the MyDiaCare program.",What was assessed to determine the benefit of MyDiaCare after 6 months of participation in the program (pmcid=10442735)?,"The benefit of MyDiaCare was assessed by the changes in glycated hemoglobin (HbA1c) levels, the proportion of patients achieving clinical and biological targets, adherence to care plans, and satisfaction after 6 months of participating in the MyDiaCare program.",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,A budget impact model was performed using data from the DNE study and another South African cohort of the DISCOVERY study to estimate the economic impact of MyDiaCare.,What data was used to estimate the economic impact of MyDiaCare in the budget impact model (pmcid=10442735)?,Data from the DNE study and another South African cohort of the DISCOVERY study was used to estimate the economic impact of MyDiaCare in the budget impact model.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Results: Between November 25, 2019, and June 30, 2020, a total of 117 patients (8 with type 1 diabetes and 109 with type 2 diabetes) were enrolled in 2 centers.","How many patients were enrolled in the study between November 25, 2019, and June 30, 2020 (pmcid=10442735)?","117 patients were enrolled in the study between November 25, 2019, and June 30, 2020 (pmcid=10442735).",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"After 6 months of MyDiaCare, a clinically relevant decrease in mean HbA1c levels of 0.6% from 7.8% to 7.2% was observed.",What was the observed decrease in mean HbA1c levels after 6 months of MyDiaCare (pmcid=10442735)?,0.6%,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Furthermore, 54% (43/79) of patients reached or maintained their HbA1c targets at 6 months.",Did 54% of patients reach or maintain their HbA1c targets at 6 months (pmcid=10442735)?,"Yes, 54% of patients reached or maintained their HbA1c targets at 6 months according to the information provided in the context.",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Most patients achieved their targets for blood pressure (53/79, 67% for systolic and 70/79, 89% for diastolic blood pressure) and lipid parameters (49/71, 69% for low-density-lipoprotein [LDL] cholesterol, 41/71, 58% for high-density-lipoprotein [HDL] cholesterol, and 59/71, 83% for total cholesterol), but fewer patients achieved their targets for triglycerides (32/70, 46%), waist circumference (12/68, 18%), and body weight (13/76, 17%).",What percentage of patients achieved their target for low-density-lipoprotein (LDL) cholesterol in the study (pmcid=10442735)?,69%,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,The mean overall adherence to the MyDiaCare care plan was 93%.,What was the mean overall adherence to the MyDiaCare care plan? (pmcid=10442735),The mean overall adherence to the MyDiaCare care plan was 93%.,
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Most patients (87/117, 74%) were satisfied with the MyDiaCare program.",Were most patients satisfied with the MyDiaCare program (pmcid=10442735)?,"Yes, most patients (74%) were satisfied with the MyDiaCare program according to the study associated with pmcid=10442735.",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"The net budget impact per patient with type 2 diabetes, older than 19 years, treated in the private sector using MyDiaCare was estimated to be approximately South African Rands (ZAR) 71,023 (US $4089) during the first year of introducing MyDiaCare.","What was the estimated net budget impact per patient with type 2 diabetes, older than 19 years, treated in the private sector using MyDiaCare during the first year of introducing MyDiaCare? (pmcid: 10442735)","The estimated net budget impact per patient with type 2 diabetes, older than 19 years, treated in the private sector using MyDiaCare during the first year of introducing MyDiaCare was approximately South African Rands (ZAR) 71,023 (US $4089).",
10442735,Makan H,"Clinical and Economic Assessment of MyDiaCare, Digital Tools Combined With Diabetes Nurse Educator Support, for Managing Diabetes in South Africa: Observational Multicenter, Retrospective Study Associated With a Budget Impact Model",2023,bim,"Conclusions: The results of using MyDiaCare program, which combines digital tools for patients and health care professionals with DNE support, suggest that it may be a clinically effective and cost-saving solution for diabetes management in the South African private health care sector.",Was the MyDiaCare program found to be a cost-saving solution for diabetes management in the South African private health care sector (pmcid=10442735)?,"Yes, the MyDiaCare program was found to be a cost-saving solution for diabetes management in the South African private health care sector, according to the study associated with pmcid 10442735.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"- Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, progressive autoimmune disease causing peripheral nervous system dysfunction.",What is chronic inflammatory demyelinating polyneuropathy (CIDP) and what does it cause? (pmcid=9910243),"Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, progressive autoimmune disease that causes peripheral nervous system dysfunction.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Guidelines recommend immunoglobulin (IG) therapy as an immunomodulatory agent in CIDP.,What do guidelines recommend as an immunomodulatory agent in CIDP? (pmcid=9910243),Immunoglobulin (IG) therapy,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Drawbacks and unmet needs with intravenous immunoglobulin (IVIG) include adverse effects and wear-off effects, along with the burden of administration based on site of care.",What are some drawbacks and unmet needs associated with intravenous immunoglobulin (IVIG) (pmcid=9910243)?,"Some drawbacks and unmet needs associated with intravenous immunoglobulin (IVIG) include adverse effects, wear-off effects, and the burden of administration based on site of care.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Subcutaneous administration of Hizentra, a subcutaneous immunoglobulin (SCIG) reduces patient burden by allowing self-administration outside the hospital setting and has fewer adverse events (AEs).",How does subcutaneous administration of Hizentra reduce patient burden and adverse events? (pmcid=9910243),Subcutaneous administration of Hizentra reduces patient burden by allowing self-administration outside the hospital setting and has fewer adverse events (AEs).,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Objective: We aimed to compare the expected cost of treatment and the budget impact of Hizentra compared with IVIG for maintenance treatment of CIDP in the United States.,What was the objective of the study comparing Hizentra with IVIG for maintenance treatment of CIDP in the United States? (pmcid=9910243),The objective of the study was to compare the expected cost of treatment and the budget impact of Hizentra compared with IVIG for maintenance treatment of CIDP in the United States.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Methods: A decision tree model was developed to estimate the expected budget impact of maintenance treatment with Hizentra for US stakeholders.,What type of model was developed to estimate the expected budget impact of maintenance treatment with Hizentra for US stakeholders? (pmcid=9910243),A decision tree model was developed.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"The model adopts primarily a US integrated delivery network perspective and, secondarily, a commercial perspective over a 1-year time horizon.",What perspective does the budget impact model of maintenance treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) adopt primarily (pmcid=9910243)?,The budget impact model primarily adopts a US integrated delivery network perspective.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Pharmacy costs were based on a payment mix of average sales price (73%), wholesale acquisition cost (2%), and average wholesale price (25%).",What were the pharmacy costs based on in the budget impact model for maintenance treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) relative to Intravenous Immunoglobulin in the United States (pmcid=9910243)?,"The pharmacy costs were based on a payment mix of average sales price (73%), wholesale acquisition cost (2%), and average wholesale price (25%).",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Costs in the model reflect 2022 US dollars.,What do the costs in the model reflect (pmcid=9910243)?,Costs in the model reflect 2022 US dollars.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"In accordance with the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines and recommendations for budget impact modeling, no discounting was performed.",Was discounting performed in accordance with ISPOR guidelines and recommendations for budget impact modeling (pmcid=9910243)?,"No, discounting was not performed in accordance with ISPOR guidelines and recommendations for budget impact modeling in the study with pmcid=9910243.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,The PATH clinical study of Hizentra maintenance in CIDP was used to determine clinical inputs for relapse rates at initial assessment (24 weeks) and at 52 weeks for Hizentra.,What clinical study was used to determine relapse rates for Hizentra maintenance in CIDP (pmcid=9910243)?,The PATH clinical study was used to determine relapse rates for Hizentra maintenance in CIDP.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,The ICE clinical study of Gamunex maintenance in CIDP was the basis of relapse rates for Gamunex (and other IVIGs).,What was the basis of relapse rates for Gamunex (and other IVIGs) in the ICE clinical study? (pmcid=9910243),The basis of relapse rates for Gamunex (and other IVIGs) in the ICE clinical study was the Gamunex maintenance in CIDP.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Literature-based estimates were obtained for infusion costs by site of care, costs of IVIG infusion-related complications, and significant IVIG AE rates.","What estimates were obtained for infusion costs, costs of IVIG infusion-related complications, and significant IVIG AE rates? (pmcid=9910243)","Literature-based estimates were obtained for infusion costs by site of care, costs of IVIG infusion-related complications, and significant IVIG AE rates.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Hizentra AE rates from the US Hizentra prescribing information were assessed but were not included in the model as the AEs in CIDP were mild, easily treated, and self-limited.",What were the adverse event rates for Hizentra assessed in the model (pmcid=9910243)?,"The adverse event rates for Hizentra were assessed from the US Hizentra prescribing information, but they were not included in the model as the adverse events in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) were mild, easily treated, and self-limited.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Sensitivity analyses and scenario analyses were conducted to evaluate variations from the base case.,What type of analyses were conducted to evaluate variations from the base case in the study (pmcid=9910243)?,Sensitivity analyses and scenario analyses were conducted to evaluate variations from the base case in the study (pmcid=9910243).,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"Results: The model showed that a Hizentra starting dose of 0.2 g/kg is expected to result in annual cost savings of US$32,447 per patient compared with IVIG.",What are the expected annual cost savings per patient with Hizentra compared to IVIG? (pmcid=9910243),"The expected annual cost savings per patient with Hizentra compared to IVIG is US$32,447.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,"For a hypothetical 25-million-member plan, the budget impact of a 10% market share shift from IVIG to Hizentra is expected to result in savings of US$2,296,235.",What is the expected savings for a hypothetical 25-million-member plan with a 10% market share shift from IVIG to Hizentra? (pmcid=9910243),"The expected savings for a hypothetical 25-million-member plan with a 10% market share shift from IVIG to Hizentra is US$2,296,235.",
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Conclusion: This analysis projects that Hizentra is likely associated with favorable economic benefit compared with IVIG in managing CIDP.,What economic benefit is projected for Hizentra compared to IVIG in managing CIDP? (pmcid=9910243),Hizentra is likely associated with favorable economic benefit compared with IVIG in managing CIDP.,
9910243,Mallick R,A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States,2023,bim,Supplementary Information: The online version contains supplementary material available at 10.1007/s41669-023-00386-2.,What supplementary material is available in the online version of the article (pmcid=9910243)?,The supplementary material available in the online version of the article with pmcid=9910243 includes additional information related to the budget impact model of maintenance treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) relative to Intravenous Immunoglobulin in the United States.,
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"- Background: Dual antiplatelet therapy (DAPT) is the recommended preventative treatment for secondary ischaemic events, but increases the risk of bleeding, potentially affecting patients’ health-related quality-of-life (HRQoL).","What is the recommended preventative treatment for secondary ischaemic events, and how does it potentially affect patients' health-related quality-of-life (pmcid=6149200)?","The recommended preventative treatment for secondary ischaemic events is Dual antiplatelet therapy (DAPT). DAPT increases the risk of bleeding, which can potentially affect patients' health-related quality-of-life (HRQoL).",0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Varied utility decrements have been used in cost-effectiveness models assessing alternative DAPT regimens, but it is unclear which of these decrements are most appropriate.",What have varied utility decrements been used for in cost-effectiveness models assessing alternative DAPT regimens (pmcid=6149200)?,Varied utility decrements have been used in cost-effectiveness models assessing alternative DAPT regimens to assess the impact of minor and major bleeding events on health-related quality of life.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Therefore, we reviewed existing sources of utility decrements for bleeds in patients receiving DAPT and undertook primary research to estimate utility decrements through a patient elicitation exercise using vignettes and the EuroQol EQ-5D.",What sources were reviewed to estimate utility decrements for bleeds in patients receiving DAPT (pmcid=6149200)?,Existing sources of utility decrements were reviewed to estimate utility decrements for bleeds in patients receiving DAPT.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Methods: MEDLINE, PubMed and references of included studies were searched.",What databases were searched in the study (pmcid=6149200)?,"MEDLINE, PubMed",0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,Primary research and decision analytic modelling studies reporting utility decrements for bleeds related to DAPT were considered.,What type of studies were considered in evaluating utility decrements for bleeds related to DAPT (pmcid=6149200)?,Primary research and decision analytic modelling studies were considered in evaluating utility decrements for bleeds related to DAPT in the study with pmcid=6149200.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"For the primary research study, 21 participants completed an elicitation exercise involving vignettes describing minor and major bleeds and the EQ-5D-3 L and EQ-5D-5 L.",What exercise did the 21 participants complete in the primary research study (pmcid=6149200)?,The 21 participants completed an elicitation exercise involving vignettes describing minor and major bleeds and the EQ-5D-3 L and EQ-5D-5 L.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,Utility decrements were derived using linear regression and compared to existing estimates.,What were utility decrements derived using linear regression compared to (pmcid=6149200)?,Existing estimates,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Results: Four hundred forty-two citations were screened, of which 12 studies were included for review.",What was the total number of citations screened for this systematic literature review (pmcid=6149200)?,442,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,Reported utility decrements ranged from − 0.002 to − 0.03 for minor bleeds and − 0.007 to − 0.05 for major bleeds.,What range of reported utility decrements were found for minor and major bleeds in the study (pmcid=6149200)?,Reported utility decrements ranged from − 0.002 to − 0.03 for minor bleeds and − 0.007 to − 0.05 for major bleeds.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Data sources used to estimate the decrements, however, lacked relevance to our population group and few studies adequately reported details of their measurement and valuation approaches.",What data sources were used to estimate the decrements in the study conducted by Doble B et al. (pmcid=6149200)?,The data sources used to estimate the decrements in the study conducted by Doble B et al. were not relevant to the population group and few studies adequately reported details of their measurement and valuation approaches.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,No study completely adhered to reimbursement agency requirements in the UK according to the National Institute for Health and Care Excellence reference case.,What requirements did no study completely adhere to in the UK according to the National Institute for Health and Care Excellence reference case (pmcid=6149200)?,No study completely adhered to reimbursement agency requirements in the UK according to the National Institute for Health and Care Excellence reference case.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Our primary research elicited utility decrements overlapped existing estimates, ranging from − 0.000848 to − 0.00828 for minor bleeds and − 0.0187 to − 0.0621 for major bleeds.",What range of utility decrements were elicited for minor and major bleeds in the primary research study (pmcid=6149200)?,"The range of utility decrements elicited for minor bleeds was -0.000848 to -0.00828, and for major bleeds was -0.0187 to -0.0621 in the primary research study (pmcid=6149200).",0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"However, the magnitude of difference depended on the instrument, estimation method and valuation approach applied.",What factors influenced the magnitude of difference in the impact of minor and major bleeding events during dual antiplatelet therapy (pmcid=6149200)?,"The factors that influenced the magnitude of difference in the impact of minor and major bleeding events during dual antiplatelet therapy included the instrument, estimation method, and valuation approach applied.",0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Conclusions: Several sources of utility decrements for bleeds are available for use in cost-effectiveness analyses, but are of limited quality and relevance.",What sources of utility decrements for bleeds are available for use in cost-effectiveness analyses (pmcid=6149200)?,"Several sources of utility decrements for bleeds are available for use in cost-effectiveness analyses, but are of limited quality and relevance.",0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Our elicitation exercise has derived utility decrements from a relevant patient population, based on standardised definitions of minor and major bleeding events, using a validated HRQoL instrument and have been valued using general population tariffs.",What utility decrements were derived from the relevant patient population in the elicitation exercise (pmcid=6149200)?,"Utility decrements from the relevant patient population in the elicitation exercise were derived based on standardised definitions of minor and major bleeding events, using a validated HRQoL instrument and valued using general population tariffs.",0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,We suggest that our utility decrements be used in future cost-effectiveness analyses of DAPT.,What should be used in future cost-effectiveness analyses of DAPT (pmcid=6149200)?,Utility decrements,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Electronic supplementary material: The online version of this article (10.1186/s12955-018-1019-3) contains supplementary material, which is available to authorized users.",What type of study was conducted to assess the health-related quality of life impact of bleeding events during dual antiplatelet therapy (pmcid=6149200)?,A systematic literature review and patient preference elicitation study.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"- Background: Dual antiplatelet therapy (DAPT) is the recommended preventative treatment for secondary ischaemic events, but increases the risk of bleeding, potentially affecting patients’ health-related quality-of-life (HRQoL).",What is the recommended preventative treatment for secondary ischaemic events according to the abstract sentence (pmcid=6149200)?,Dual antiplatelet therapy (DAPT),0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Varied utility decrements have been used in cost-effectiveness models assessing alternative DAPT regimens, but it is unclear which of these decrements are most appropriate.",What have varied utility decrements been used for in cost-effectiveness models assessing alternative DAPT regimens (pmcid=6149200)?,Varied utility decrements have been used in cost-effectiveness models assessing alternative DAPT regimens to assess the impact of minor and major bleeding events on health-related quality of life.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Therefore, we reviewed existing sources of utility decrements for bleeds in patients receiving DAPT and undertook primary research to estimate utility decrements through a patient elicitation exercise using vignettes and the EuroQol EQ-5D.",What sources did the study review to estimate utility decrements for bleeds in patients receiving DAPT (pmcid=6149200)?,The study reviewed existing sources of utility decrements for bleeds in patients receiving DAPT.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Methods: MEDLINE, PubMed and references of included studies were searched.",What databases were searched in the study (pmcid=6149200)?,MEDLINE and PubMed,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,Primary research and decision analytic modelling studies reporting utility decrements for bleeds related to DAPT were considered.,What type of studies were considered in the systematic literature review regarding the impact of minor and major bleeding events during dual antiplatelet therapy (pmcid=6149200)?,Primary research and decision analytic modelling studies were considered in the systematic literature review regarding the impact of minor and major bleeding events during dual antiplatelet therapy (pmcid=6149200).,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"For the primary research study, 21 participants completed an elicitation exercise involving vignettes describing minor and major bleeds and the EQ-5D-3 L and EQ-5D-5 L.",What exercise did the 21 participants complete in the primary research study (pmcid=6149200)?,The 21 participants completed an elicitation exercise involving vignettes describing minor and major bleeds and the EQ-5D-3 L and EQ-5D-5 L.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,Utility decrements were derived using linear regression and compared to existing estimates.,What were the utility decrements derived using linear regression compared to in this study (pmcid=6149200)?,The utility decrements were compared to existing estimates in this study.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Results: Four hundred forty-two citations were screened, of which 12 studies were included for review.",What was the total number of citations screened for this systematic literature review (pmcid=6149200)?,442,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,Reported utility decrements ranged from − 0.002 to − 0.03 for minor bleeds and − 0.007 to − 0.05 for major bleeds.,What is the range of reported utility decrements for minor and major bleeds during dual antiplatelet therapy (pmcid=6149200)?,"The range of reported utility decrements for minor bleeds is -0.002 to -0.03, and for major bleeds is -0.007 to -0.05 during dual antiplatelet therapy.",0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Data sources used to estimate the decrements, however, lacked relevance to our population group and few studies adequately reported details of their measurement and valuation approaches.",What data sources were used to estimate the decrements in the study conducted by Doble B et al. (pmcid=6149200)?,The data sources used to estimate the decrements in the study conducted by Doble B et al. (pmcid=6149200) lacked relevance to the population group and few studies adequately reported details of their measurement and valuation approaches.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,No study completely adhered to reimbursement agency requirements in the UK according to the National Institute for Health and Care Excellence reference case.,What requirements did no study completely adhere to in the UK according to the National Institute for Health and Care Excellence reference case (pmcid=6149200)?,No study completely adhered to reimbursement agency requirements in the UK according to the National Institute for Health and Care Excellence reference case.,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Our primary research elicited utility decrements overlapped existing estimates, ranging from − 0.000848 to − 0.00828 for minor bleeds and − 0.0187 to − 0.0621 for major bleeds.",What range of utility decrements were elicited for minor and major bleeds in the primary research study (pmcid=6149200)?,"The range of utility decrements elicited for minor bleeds was -0.000848 to -0.00828, and for major bleeds was -0.0187 to -0.0621 in the primary research study (pmcid=6149200).",0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"However, the magnitude of difference depended on the instrument, estimation method and valuation approach applied.",What factors influenced the magnitude of difference in the impact of minor and major bleeding events during dual antiplatelet therapy (pmcid=6149200)?,"The magnitude of difference in the impact of minor and major bleeding events during dual antiplatelet therapy was influenced by the instrument, estimation method, and valuation approach applied.",0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Conclusions: Several sources of utility decrements for bleeds are available for use in cost-effectiveness analyses, but are of limited quality and relevance.",What sources of utility decrements for bleeds are available for use in cost-effectiveness analyses (pmcid=6149200)?,"Several sources of utility decrements for bleeds are available for use in cost-effectiveness analyses, but are of limited quality and relevance.",0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Our elicitation exercise has derived utility decrements from a relevant patient population, based on standardised definitions of minor and major bleeding events, using a validated HRQoL instrument and have been valued using general population tariffs.",What utility decrements were derived from the relevant patient population in the elicitation exercise (pmcid=6149200)?,"Utility decrements from the relevant patient population in the elicitation exercise were derived based on standardised definitions of minor and major bleeding events, using a validated HRQoL instrument and valued using general population tariffs.",0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,We suggest that our utility decrements be used in future cost-effectiveness analyses of DAPT.,What should be used in future cost-effectiveness analyses of DAPT according to the abstract sentence? (pmcid=6149200),Utility decrements,0bdde4c99dc5699c5aa1e963d2e46b46
6149200,Doble B,Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study,2018,slr_cem,"Electronic supplementary material: The online version of this article (10.1186/s12955-018-1019-3) contains supplementary material, which is available to authorized users.",What type of study was conducted in this research article (pmcid=6149200)?,Systematic literature review and patient preference elicitation study,0bdde4c99dc5699c5aa1e963d2e46b46
